Literature DB >> 17392172

The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.

Akiko Kunita1, Takeshi G Kashima, Yasuyuki Morishita, Masashi Fukayama, Yukinari Kato, Takashi Tsuruo, Naoya Fujita.   

Abstract

Tumor cell-induced platelet aggregation has been reported to facilitate hematogenous metastasis. Aggrus/podoplanin is a platelet aggregation-inducing factor that is up-regulated in a number of human cancers and has been implicated in tumor progression. We studied herein the role of Aggrus in tumor growth, metastasis , and survival in vivo. Aggrus expression in Chinese hamster ovary cells promoted pulmonary metastasis in both an experimental and a spontaneous mouse model. No differences in the size of metastatic foci or in primary tumor growth were found in either set of mice. Aggrus expressing cells , which were covered with platelets, arrested in the lung microvasculature 30 minutes after injection. In addition, lung metastasis resulting from Aggrus expression decreased the survival of the mice. By generating several Aggrus point mutants, we revealed that point mutation at the platelet aggregation-stimulating domain of Aggrus(Thr34 and Thr52) obliterated both platelet aggregation and metastasis. Furthermore, administration of aspirin to mice reduced the number of metastatic foci. These results indicate that Aggrus contributes to the establishment of metastasis by promoting platelet aggregation without affecting subsequent growth. Thus, Aggrus could serve as an ideal therapeutic target for drug development to block metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392172      PMCID: PMC1829466          DOI: 10.2353/ajpath.2007.060790

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Discovery of the shortest sequence motif for high level mucin-type O-glycosylation.

Authors:  A Yoshida; M Suzuki; H Ikenaga; M Takeuchi
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

2.  Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I).

Authors:  G Zimmer; F Lottspeich; A Maisner; H D Klenk; G Herrler
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

3.  Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.

Authors:  Ping Yuan; Stephane Temam; Adel El-Naggar; Xian Zhou; Diane D Liu; J Jack Lee; Li Mao
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

4.  Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.

Authors:  P Salven; A Orpana; H Joensuu
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

5.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium.

Authors:  S Breiteneder-Geleff; A Soleiman; H Kowalski; R Horvat; G Amann; E Kriehuber; K Diem; W Weninger; E Tschachler; K Alitalo; D Kerjaschki
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

6.  P-selectin deficiency attenuates tumor growth and metastasis.

Authors:  Y J Kim; L Borsig; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Protection from tumor necrosis factor-mediated cytolysis by platelets.

Authors:  C Philippe; B Philippe; B Fouqueray; J Perez; M Lebret; L Baud
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

8.  Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.

Authors:  N Esumi; D Fan; I J Fidler
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

9.  Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors.

Authors:  Yukinari Kato; Isoji Sasagawa; Mika Kaneko; Motoki Osawa; Naoya Fujita; Takashi Tsuruo
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

10.  Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.

Authors:  R Salgado; P B Vermeulen; I Benoy; R Weytjens; P Huget; E Van Marck; L Y Dirix
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  69 in total

Review 1.  Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?

Authors:  Ana Sofia Azevedo; Gautier Follain; Shankar Patthabhiraman; Sébastien Harlepp; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2015-08-27       Impact factor: 3.405

2.  Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.

Authors:  Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

3.  Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1.

Authors:  Liang Gong; Yun Cai; Xiangdong Zhou; Heping Yang
Journal:  Pathol Oncol Res       Date:  2012-04-26       Impact factor: 3.201

4.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

5.  Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2.

Authors:  Chawaree Chaipan; Imke Steffen; Theodros Solomon Tsegaye; Stephanie Bertram; Ilona Glowacka; Yukinari Kato; Jan Schmökel; Jan Münch; Graham Simmons; Rita Gerardy-Schahn; Stefan Pöhlmann
Journal:  Retrovirology       Date:  2010-05-19       Impact factor: 4.602

6.  Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.

Authors:  Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

7.  Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells.

Authors:  Hanako Suzuki; Mitsuho Onimaru; Yoshikazu Yonemitsu; Yoshihiko Maehara; Seiji Nakamura; Katsuo Sueishi
Journal:  Mol Cancer       Date:  2010-10-31       Impact factor: 27.401

8.  The roles of platelet GPIIb/IIIa and alphavbeta3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow.

Authors:  Yiyao Liu; Fenglong Zhao; Wentian Gu; Haishiu Yang; Quoquan Meng; Yunxiang Zhang; Hong Yang; Qi Duan
Journal:  J Biomed Biotechnol       Date:  2009-10-28

9.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18

10.  Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice.

Authors:  Deng-Bo Ji; Jia Ye; Yi-Min Jiang; Bo-Wen Qian
Journal:  BMC Complement Altern Med       Date:  2009-07-01       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.